Insight Pharmaceuticals voluntarily recalls one lot of Nostrilla

LANGHORNE, Pa. — Insight Pharmaceuticals is voluntarily recalling one lot of a nasal decongestant due to the possibility of bacterial contamination, the company said.

Insight said it would recall lot number 11G075, UPC code 6373673005, of Nostrilla nasal spray to the consumer level because of possible contamination with Burkholderia cepacia bacteria. The lot, which contains 34,092 bottles, was distributed nationwide to retail outlets.

“It is our commitment to our customers to provide them with products  they can rely on as safe and effective for their [Food and Drug Administration]-approved uses,”  Insight CEO Gary Downing said. “Through our standard testing procedures and protocols, we discovered the potential  presence of a bacterial contaminant in one lot of Nostrilla and reported it to the FDA. Consumer safety is our No. 1 priority, and we'll take all necessary action to ensure Nostrilla, as well as all of our products, comply with FDA regulations and requirements."

Burkholderia cepacia can cause serious infections in people with compromised immune systems or chronic lung conditions, though the possibility of infection is remote in healthy people, the drug maker said, and no illnesses have been reported to date in connection with the recalled lot.

Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.